ArticleFrontiers in health services2026
Trends in the China pathologist workforce From 2010 to 2022.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pathology faces a global personnel shortage and increasing workload due to rising cancer cases and diagnostic complexity, yet data in China are lacking. This study examines trends in China's pathology workforce from 2010 to 2022. Methods: Data during 2010-2022 were collected from the China Health Statistical Yearbook, including the proportion of pathologists among physicians, oncology clinic outpatients, and discharged tumor patients. Data on new cancer cases and incidence rates from 2010 to 2018 were obtained from the China Cancer Registry Annual Report. We calculated ratio metrics (workload per pathologist) and growth rates, and performed descriptive linear regression to assess workforce demand balance. Results: From 2010 to 2022, the proportion of pathologists among physicians remained stable in China, while the estimated absolute number increased. Concurrently, the estimated national new cancer cases rose. Due to the increase in pathologist density (per million population), the estimated average cancer case load per pathologist decreased from 331.86 in 2010 to 215.29 in 2018. However, from 2010 to 2022, oncology clinic outpatients and inpatient tumor patients per pathologist increased by 131.42% and 46.98%, respectively. Growth rate analyses showed that oncology clinic outpatients and inpatient tumor patients increased by 325.28% and 170.10%, respectively, whereas the pathologist workforce increased by 83.77%. Descriptive linear regressions indicated positive correlations between pathologist numbers and patient volumes (all Conclusions: Although the pathologist workforce has grown in China, its growth has not kept pace with the rising diagnostic demand. The correlation between tumor patient volume and pathologist numbers highlights the need for workforce planning and efficiency-enhancing technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.